Lora Novakovic Lackovic

Dr. Lora Novakovic Lackovic

Clinic for Lung Disease University Clinical Center Republic Srpska
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
MTMilica Srecic Tomic
Milica Srecic Tomic
MNMarko Novakovic
Marko Novakovic
MTMirko Turic
Mirko Turic
AKAleksandra Kajkut
Aleksandra Kajkut
RGRanko Glamocak
Ranko Glamocak
Background: Immune checkpoint inhibitors (ICIs) have become the standard first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) without targetable mutations. This study aimed to assess real-world outcomes of pembrolizumab monotherapy in patients with high PD-L1 expression (≥50%) and compare them with results from the KEYNOTE-024 clinical trial.Methods: This retrospective study included patients with advanced or metastatic NSCLC treated with pembrolizumab as first-line therapy at the Clinic for Pulmonary Diseases, University Clinical Center of Republika Srpska, between January 2018 and December 2022. Clinical and pathological data were collected from medical records and analyzed using descriptive and inferential statistical methods.Results: The cohort included 46 patients with a median age of 64 years; 56.5% were aged ≥65, 73.9% were male, 76% were smokers, and 72% had an ECOG performance status of 1. Adenocarcinoma (AC) and squamous cell carcinoma (SCC) were diagnosed in 50 and 46% of cases, respectively, while 70% had metastatic disease and 15% had brain metastases. The two-year objective response rate (ORR) was 72.2%, lower than the 85.7% reported in KEYNOTE-024, possibly due to differences in PD-L1 assay (SP263 vs. 22C3) and patient selection. Despite this, the median overall survival (OS) was 36 months—higher than in the trial. One-, two-, and three-year survival rates were 57.9, 53.5, and 42.8%, respectively.Conclusion: Our findings confirm the clinical benefit of pembrolizumab in a real-world setting, despite lower ORR compared to clinical trial data. However, the prognosis remains guarded due to the advanced stage and comorbidities of the population. Further investigation is warranted to optimize patient selection and treatment strategies.

1 January 2023 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
LLLjilja Latinovic-Tadic
Ljilja Latinovic-Tadic
Mirko Jevto StaneticMirko Jevto Stanetic
Mirko Jevto Stanetic
MLMarko Lackovic
Marko Lackovic
Background/Aim. The fact that lung carcinomas, like other solid tumors, can be immunogenic may have a substantial prognostic value in non-small cell lung cancer (NSCLC). Specific cytotoxic T-lymphocytes (CTL) can be demonstrated in most patients with primary tumors of different histological types. Two main groups of T-lymphocytes participate in the coupled recognition of tumor-specific antigens ? CTL (CD8+) and helper T-lymphocytes (CD4+). The aim of the study was to assess the relationship between the tumor infiltration of T-lymphocytes and the therapeutic response to initial chemotherapy. Methods. Data were obtained from patients with NSCLC whose therapeutic response after four cycles of initial platinum-based chemotherapy was observed in relation to the density of tumor-infiltrating T-lymphocytes (CD4+ and CD8+) in small tumor biopsy samples. The therapeutic response was assessed in line with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 therapeutic response evaluation system. Based on the expected therapeutic response, the patients were divided into three groups: favorable therapeutic response patients (complete and partial regression), stable disease patients, and disease progression patients. To assess the density of CD4+ and CD8+ T-lymphocytes, the number of lymphocytes was determined at ?200 magnification (1.1 mm2). Three visual fields with the densest lymphocyte infiltrate were selected for counting, and the values of all individual fields were added up. Based on the mean value, the samples were classified into the following groups: score 0, score 1, score 2, and score 3. During statistical data processing, low infiltration density combined score 0 and score 1 groups, and high infiltration density combined score 2 and score 3 groups. Based on the collected data, a database was created in SPSS 22.0 software and used for further statistical analysis. Statistical analysis of the data included descriptive and analytical statistics methods. Results. There was no significant difference in the distribution of CD4+ T-lymphocytes and CD8+ T-lymphocytes in the epithelial component of the tumor between patients with a different therapeutic response (?2 = 2.977; p = 0.226 and ?2 = 1.329; p = 0.515, respectively). There was no significant influence of the infiltration density of CD4+ T-lymphocytes and CD8+ T-lymphocytes in the stromal component of the tumor on the therapeutic response (?2 = 0.606; p = 0.739 and ?2 = 5.167; p = 0.076, respectively). Conclusion. The research did not prove that patients with a high level of tumor-infiltrating CD4+ and CD8+ T-lymphocytes in the epithelial and stromal component of the NSCLC had a better therapeutic response to standard initial chemotherapy.

1 January 2024 in SCRIPTA MEDICA
Verified
Journal Article
Open access
PDF file
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
SUSonja Ukmar
Sonja Ukmar
MDMladen Duronjić
Mladen Duronjić
MSMilica Srećić-Tomić
Milica Srećić-Tomić
MKMarko Kantar
Marko Kantar
Atypical lung carcinoids are rare compared to other lung cancers and are classified as tumours of medium malignancy. Pulmonary tuberculosis is the second leading cause of death from infectious diseases. The paper presents the case of a 46-year-old female patient who was surgically treated during acute tuberculosis. The patient recovered and is under the supervision of a pulmonologist oncologist.

25 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SUSefika Umihanic
Sefika Umihanic
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
LNLejla Alidzanovic Nurkanovic
Lejla Alidzanovic Nurkanovic
MKMedina Bandovic Kuduzovic
Medina Bandovic Kuduzovic
AŠAnida Šehić
Anida Šehić
NSNejra Selak
Nejra Selak
Background/Objectives: Squamous cell lung cancer (SCC) presents a significant treatment challenge due to its poor prognosis and limited therapeutic options. In many resource-limited countries, access to advanced molecular testing is often unavailable, making the identification of novel and reliable prognostic markers crucial for improving patient selection for systemic treatments. Methods: This single-center, retrospective study investigated the prognostic value of inflammatory biomarkers, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), in 134 patients diagnosed with SCC. Patients were stratified into groups based on optimal cut-off values determined by ROC analysis for each biomarker. Results: Elevated levels of the SII, NLR, and PLR were significantly associated with shorter overall survival in patients with SCC (all p < 0.05). Conclusions: These easily accessible and cost-effective laboratory parameters are particularly valuable in settings where molecular testing is not available, aiding in the identification of high-risk patients and optimizing treatment selection for chemotherapy.

10 May 2019 in Medicinski Glasnik
Verified
Journal Article
Open access
PDF file
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
LTLjilja Latinović Tadić
Ljilja Latinović Tadić
Mirko Jevto StaneticMirko Jevto Stanetic
Mirko Jevto Stanetic
NTNataša Tanasković
Nataša Tanasković
SMSlavica Marić
Slavica Marić
MLMarko Lacković
Marko Lacković
Aim Retrospective analysis of disease clinical course with a purpose of defining potential prognostic parameters which are essential for optimal target therapy. Methods The study involved 29 patients with histologically confirmed lung adenocarcinoma and existing epidermal growth factor receptor (EGFR) mutations, which are treated by tyrosine kinase inhibitors (TKI). ResultsAllegations of a larger prevalence in women and non-smokers were found. The study confirmed dominance of mutations on exon 19 and exon 21. Usefulness of the treatment with erlotinib in terms of increasing survival time was evident. Median survival of patients in the survey sample was 14.5 months. Median survival in relation to gender or smoking status did not show statistical significance. ConclusionConsidering obtained results, we have confirmed that patients with advanced lung adenocarcinoma and present mutations of epidermal growth factor receptor, who had been treated with first generation TKI, had median survival time of over a year.

1 January 2026 in Respiratio
Verified
Journal Article
Closed access
BMBrankica Marković-Furtula
Brankica Marković-Furtula
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
SUSonja Ukmar
Sonja Ukmar
Introduction: Tuberculosis (TB) in older adults represents a particular health challenge due to weakened immunity, frequent comorbidities, and atypical clinical presentation. The aim: Analysis the clinical-epidemiological characteristics, comorbidities, adverse treatment effects, and outcomes of TB in patients over 65 years of age. Methods: A retrospective observational cohort study included 154 patients treated for tuberculosis at the Clinic for Pulmonary Diseases, University Clinical Center of the Republic of Srpska, between January 2023 and December 2025. Demographic data, microbiological findings, comorbidities, disease localization, drug resistance, and treatment outcomes were analyzed, and the results were compared with current international literature. Results: Of the total 154 patients, 44.16% (n=68) were older than 65 years. The most frequent comorbidities were diabetes mellitus (30.88%), chronic obstructive pulmonary disease (16.17%), and lung cancer (5.88%). Smoking was significantly less common among older patients (36.76% vs. 81.40%). Pulmonary TB was the predominant localization in both groups (>94%). The most common adverse treatment effects in older patients were hyperuricemia (40%), elevated liver enzymes (25%), and gastrointestinal disturbances (16%). Rifampicin resistance was observed in 1.46% of older patients compared to 5.81% of younger ones. Successful treatment was achieved in 48.51% of older patients, while loss to follow-up was high (38.25%). The highest mortality rate was recorded among older patients without comorbidities (7.40%). Conclusion: Tuberculosis in older adults is marked by frequent comorbidities, more adverse drug effects, and a significant proportion of patients lost to follow-up. These findings highlight the need for specific geriatric TB programs. The treatment success rate should be raised to the World Health Organization target level (≥85%).